Lercanidipine rights for Canada to Fournier
France's Fournier says that its Canadian affiliate has acquiredmarketing rights from Recordati of Italy for the latter's calcium channel blocker lercanidipine, currently sold elsewhere as Zanidip. As part of the deal, Fournier Pharma will submit a New Drug Submission in Canada by the end of the year.
Recordati noted that lercanidipine has now been approved in 31 countries and is marketed in 25. The firm's chairman, Giovanni Recordati, said that the finalization of other licensing agreements for the drug (the group has also signed up with Solvay in Australia and Laboratorios Sanfer in Mexico) means deals are now in place in 19 out of the top 20 world pharmaceutical markets. Recordati recently completed an 800-patient study looking at the tolerability of lercanidipine, and said that a US filing is on track for the second half of this year (Marketletter June 25) by partner Forest Laboratories.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze